Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.47 |
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841878 | 1.00 | MAOA (0.47) | MAOAMAOBCYP19A1PTGS2HMOX2 | |
| SCHEMBL6985342 | 0.90 | MAOA (0.49) | MAOAMAOBCYP19A1PTGS2 | |
| SCHEMBL6841876 | 0.81 | CYP19A1 (0.42) | CYP19A1PTGS2HMOX2 | |
| SCHEMBL6307113 | 0.80 | CYP19A1 (0.39) | CYP19A1PTGS2 | |
| SCHEMBL6171100 | 0.79 | MIF (0.48) | CYP19A1PTGS2 | |
| SCHEMBL6171106 | 0.79 | MIF (0.48) | CYP19A1PTGS2 | |
| SCHEMBL6299812 | 0.79 | CYP19A1 (0.42) | CYP19A1PTGS2HMOX2 | |
| SCHEMBL6300300 | 0.79 | CYP19A1 (0.42) | CYP19A1PTGS2HMOX2 | |
| SCHEMBL6703598 | 0.79 | CYP19A1 (0.45) | CYP19A1PTGS2 | |
| SCHEMBL6299533 | 0.79 | CYP19A1 (0.40) | CYP19A1PTGS2HMOX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | claimed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | claimed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | claimed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | claimed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | MAOA 116/4885MAOB 139/4885CYP19A1 203/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | MAOA 116/4885MAOB 139/4885CYP19A1 203/4885 |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | MAOA 3197/4885MAOB 2947/4885CYP19A1 962/4885 |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | MAOA 3541/4885MAOB 3449/4885CYP19A1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.